Immuron Limited, a biopharmaceutical company, focuses on the research and development of polyclonal antibodies for the treatment and prevention of various diseases in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. It has a technology platform that produces antibodies to treat various diseases, including infectious diseases, cancers, and chronic inflammatory diseases. The company markets Travelan for the prevention of travellers' diarrhea. Its lead product candidate IMM-124E is in Phase II clinical trials for NASH and ASH. The company has a research and development collaboration agreement with the Walter Reed Army Institute of Research; and Naval Medical Research Center. Immuron Limited was founded in 1994 and is based in Blackburn North, Australia.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:IMRN
CUSIPN/A
Phone61-3-9824-5254
Debt
Debt-to-Equity RatioN/A
Current Ratio5.24
Quick Ratio3.32
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.05 million
Price / Sales1,550.18
Cash FlowN/A
Price / CashN/A
Book Value$0.04 per share
Price / Book285.00
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees7
Outstanding Shares142,780,000
Market Cap$1,627.67
IMMURON Ltd/S (NASDAQ:IMRN) Frequently Asked Questions
What is IMMURON Ltd/S's stock symbol?
IMMURON Ltd/S trades on the NASDAQ under the ticker symbol "IMRN."
What price target have analysts set for IMRN?
1 Wall Street analysts have issued twelve-month price targets for IMMURON Ltd/S's stock. Their forecasts range from $20.00 to $20.00. On average, they expect IMMURON Ltd/S's share price to reach $20.00 in the next year. This suggests a possible upside of 75.4% from the stock's current price. View Analyst Ratings for IMMURON Ltd/S.
What is the consensus analysts' recommendation for IMMURON Ltd/S?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IMMURON Ltd/S in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
Who are some of IMMURON Ltd/S's key competitors?
Some companies that are related to IMMURON Ltd/S include Catalent (CTLT), Ionis Pharmaceuticals (IONS), Dr.Reddy's Laboratories (RDY), United Therapeutics (UTHR), Loxo Oncology (LOXO), FibroGen (FGEN), Agios Pharmaceuticals (AGIO), GALAPAGOS NV/S (GLPG), Ligand Pharmaceuticals (LGND), Taro Pharmaceutical Industries (TARO), Madrigal Pharmaceuticals (MDGL), GW Pharmaceuticals (GWPH), HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE) and Array Biopharma (ARRY).
Who are IMMURON Ltd/S's key executives?
IMMURON Ltd/S's management team includes the folowing people:
- Dr. Jerry Kanellos Ph.D., Interim Chief Exec. Officer (Age 57)
- Mr. Peter Anastasiou, Exec. Vice Chairman (Age 58)
- Mr. Phillip Allen Hains, Joint CFO & Company Sec. (Age 59)
- Mr. Peter Vaughan, Joint CFO & Company Sec. (Age 35)
- Mr. David Lyon, Head of Marketing
When did IMMURON Ltd/S IPO?
(IMRN) raised $6 million in an IPO on Friday, June 9th 2017. The company issued 600,000 shares at $9.99 per share. Joseph Gunnar and Rodman & Renshaw (a unit of H.C. Wainwright & Co.) served as the underwriters for the IPO and WallachBeth Capital was co-manager.
Has IMMURON Ltd/S been receiving favorable news coverage?
Press coverage about IMRN stock has been trending somewhat positive on Monday, Accern reports. The research firm rates the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. IMMURON Ltd/S earned a media sentiment score of 0.08 on Accern's scale. They also assigned media coverage about the company an impact score of 45.21 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
How do I buy shares of IMMURON Ltd/S?
Shares of IMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is IMMURON Ltd/S's stock price today?
One share of IMRN stock can currently be purchased for approximately $11.40.
How big of a company is IMMURON Ltd/S?
IMMURON Ltd/S has a market capitalization of $1.63 billion and generates $1.05 million in revenue each year. IMMURON Ltd/S employs 7 workers across the globe.
How can I contact IMMURON Ltd/S?
IMMURON Ltd/S's mailing address is 25 37 CHAPMAN STREET, VICTORIA C3, 3130. The company can be reached via phone at 61-3-9824-5254 or via email at [email protected]
MarketBeat Community Rating for IMMURON Ltd/S (NASDAQ IMRN)
MarketBeat's community ratings are surveys of what our community members think about IMMURON Ltd/S and other stocks. Vote "Outperform" if you believe IMRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMRN will underperform the S&P 500 over the long term. You may vote once every thirty days.
